Viking Therapeutics: A Biotech Balancing Act Between Promise and Financial Pressure

The competitive landscape for obesity treatments is heating up, fueling speculation about potential industry consolidation. At the center of this discussion is Viking Therapeutics, a clinical-stage biotech whose advanced drug candidate has made it a frequent subject of takeover rumors. However, the company’s story is one of contrasting narratives: significant clinical progress paired with mounting financial losses and no commercial revenue.

Clinical Pipeline Drives Valuation Speculation

Viking’s primary asset, VK2735, is a dual GLP-1/GIP receptor agonist in late-stage development. This candidate is the cornerstone of the company’s value and the primary reason it is viewed as an attractive acquisition target, especially following the recent bidding war between Pfizer and Novo Nordisk for Metsera.

The clinical program is advancing robustly. In November, Viking announced it completed enrollment for the VANQUISH-1 Phase 3 trial ahead of schedule and above its target. This 78-week study is evaluating subcutaneous VK2735 in adults with obesity. The company’s broader pipeline includes:
* An oral formulation of VK2735, which has already demonstrated statistically significant weight reduction in a Phase 2 study.
* A study investigating maintenance dosing regimens to sustain weight loss.
* A separate DACRA program developing novel dual amylin and calcitonin receptor agonists.

Recent data presented at ObesityWeek 2025 from the VENTURE study showed that after 13 weeks of treatment with VK2735, patients experienced improved cardiometabolic parameters and a reduced frequency of prediabetes and metabolic syndrome.

Soaring Costs Reflect Aggressive Development

This rapid clinical expansion comes at a steep financial cost. Viking Therapeutics reported a net loss of $90.8 million, or $0.81 per share, for the third quarter of 2025. This compares to a loss of $24.9 million ($0.22 per share) in the same period a year prior.

The driver of this increased loss is a dramatic rise in research and development spending, which surged to $90.0 million in Q3 2025 from $22.8 million in the prior-year quarter. This underscores the company’s strategy of channeling nearly all available capital into its clinical programs.
* Q3 2025 Net Loss: $90.8 million
* Q3 2025 R&D Expenditure: $90.0 million
* Cash and Equivalents: Approximately $714.6 million

Should investors sell immediately? Or is it worth buying Viking Therapeutics?

While the current cash position provides a runway for ongoing trials, the persistent high cash burn rate in the absence of product revenue remains a key risk factor for investors.

Market Performance and Analyst Sentiment

Despite the promising pipeline, Viking’s shares have faced recent pressure. The stock closed at $36.15 yesterday, down 2.51%, underperforming the S&P 500’s 0.16% decline. On a monthly basis, the stock is down approximately 5.19%, even as the broader medical sector advanced 1.12%.

The current price sits well below the 52-week high of around $50.60. This cautious trading reflects market sentiment following Phase 2 data for the oral version of VK2735, which in August showed a 20% discontinuation rate in the treatment group due to side effects.

Nevertheless, analyst outlook remains largely constructive. Canaccord Genuity maintains a “Buy” rating and recently raised its price target from $106 to $107 per share, arguing the stock is significantly undervalued. The firm highlights Viking’s advanced obesity pipeline and its positioning as a leading biotech in the field.

The consensus average price target among analysts stands at $93.39, implying substantial upside from current levels. Zacks Investment Research gives the stock a Rank of #3 (Hold) and notes its industry group, “Medical – Biomedical and Genetics,” ranks in the top 36% of all sectors it covers.

Looking ahead, consensus estimates project a loss of $0.89 per share for the upcoming quarterly report. These anticipated losses underscore the company’s heavy investment in clinical development—a strategy that pressures short-term financials but is deemed critical for advancing core programs like VK2735.